305P - Response to bortezomib in newly diagnosed multiple myeloma- a single centre experience from India

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Anti-Cancer Agents & Biologic Therapy
Plasma Cell Dyscrasias
Presenter Varun Rajan
Citation Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526
Authors V. Rajan1, G. N2, S.G. Nair2
  • 1Medical Oncology, Regional Cancer Centre Thiruvananthapuram/Trivandrum, 695011 - Thiruvananthapuram (Trivandrum)/IN
  • 2Medical Oncology, Regional Cancer Centre Thiruvananthapuram/Trivandrum, Thiruvananthapuram (Trivandrum)/IN

Abstract

Aim/Background

To study the clinical presentation and response to treatment in patients with newly diagnosed myeloma who were treated with Bortezomib containing regimens

Methods

This is a retrospective analysis of patients diagnosed as multiple myeloma during the period 2011- 2013 in the department of Medical Oncology at Regional Cancer Centre, Trivandrum, India and have received chemotherapy with Bortezomib based regimen as frontline. These patients were followed up till date.

Results

Forty one patients diagnosed as multiple myeloma during the period 2011-2013 received front line Bortezomib based chemotherapy. There were 23 males and 18 females. The median age at presentation was 52 years. The predominant symptom was bone pain in 38 patients. Twenty four patients had a Haemoglobin <10 gm% and 11 had raised serum creatinine. Fifteen patients had ISS stage 1 disease (International Staging System), 9 patients had ISS 2, and 16 had ISS 3. Twenty five patients had IgG myeloma, 8 had IgA, 6 patients had only light chain disease and 2 were non secretory. Forty one patients received 6 cycles of Bortezomib based chemotherapy for Induction. Peripheral blood stem cell transplantation was done in 6 as consolidation. Twenty eight patients achieved very good partial response (VGPR) or more after induction. Six patients had progressive disease and five patients died. The median survival of the series is 36 months and the 2 year survival is 85%.

Conclusions

Bortezomib based chemotherapy is highly effective in newly diagnosed myeloma resulting in more than VGPR in 74% of patients in this study. IgG myeloma was the predominant subtype (60%). Bortezomib based induction therapy significantly improved Overall Survival (OS) in previously untreated patients. 85% of patients attained 24 months of OS and median survival of the series was 36 months.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.